Lots of activity just been posted up on the Faron website - 6 events/meetings/conferences in the next 4 months .
https://www.faron.com/investors/calendar
Oncology / Hematology meetings , plus firstly an Investor event in mid March .
Steady and sensible - build up the company now .
The Company anticipates converting 9 research sites to FDA approved configuration and clinical use, selling 75 to 100 Xenoview Gas Blend cylinders and 15 to 20 Polarizer systems over the next 24 months.
The Company will focus Business Development activities with respiratory drug and radiology contrast agent manufacturers, pulmonary drug clinical trial CROs, and MRI system manufacturers to monetize their use of our technology to leverage their commercial activities.
https://twitter.com/FaronPharm/status/1623637096433958913?s=20&t=lNy-AKP6s1gcCImO6Gf1nA
Looks like a team building weekend .
Makes you appreciate how many people are working behind the scenes on Bex , and getting this progressed .
They look a happy bunch to be honest , and you can imagine the morale is pretty high at the moment .
Late 2019 for me , but started adding big time March 2020 .
Always remember buying a pile at about 2.5p during the slump , then literally a minute later a GH director buy RNS landed.
And that was the start of the epic rise .
Did take a good chunk off at 24p , then started adding again at 14p , and now hold more shares than I've ever had .
Bought a big wedge last week before the Newmont news . Wasn't expecting a nice rise , just felt I needed more shares as I was still averaging down.
Plus this is just a share that just draws you back in .
Average is now 8p exactly , so now sitting back and looking forward to developments .
Timo owned about 7% back in April 2019 , which was about 2.5 million shares ( only 35 million in total)
He now owns 20% , which is about 20 million shares ( from a total of 63 million )
So he's added 17.5 million shares since that low point in 2019 when the SP was 65p , but since then the placings have been from £1 through to £2.80 odd , and he's added all through that period .
The bulk of his purchases have been in the last few years , and although I expect he probably swept up a good chunk under a quid , he's also had to pay a lot more for much of them too , particularly recently .
So he probably has an average similar to many LTH's , perhaps £1.80 or perhaps a bit more . I don't know really its just a guess. It may be higher as many were adding in the £7-8 zone in 2018 .
Either way - I don't see him starting to dump shares if we get to £5 or £7 through some breakthrough news .
The commitment he's shown , like many of us in our own ways , leads me to think that he will be here right until the ultimate goal is achieved .
I guess it depends on what its approved for .
Approval for AML would give us a lift off , but its the further approvals where bigger money would come .
What one license would do is fund the rest of the trials .
Similar in some respects to Avacata , where they have multiple uses lined up , just need one approval and they are self sufficient and able to prove up the next ones in the pipeline .
In that situation , unless the company gets bought out , the SP should rerate and then build as further progress is made .
Liam , I echo Saints7 comments . Really appreciate all your efforts . This last interview may really go down as a classic . I enjoy all your youtube vids . Long may they continue as this new chapter of GGP begins .
Another drug gets FDA approval with LLS support .
They sure seem to be able to pick winners .
https://www.lls.org/news/fda-approves-new-targeted-treatment-cllsll?utm_source=Twitter&utm_medium=Social&utm_campaign=02-07-2023-LLS-FDA-Approval-CLL-SLL-ZGM
It's been holding steady since the placing ,which is a good sign , although we all know that drift can set in .
I think this time the news flow regarding Bexmab could come from multiple sources , so people are holding tight .
We now know they aren't expecting MATINS feedback until March at the earliest , but that's only a few weeks away , and any positive action to do with the Leukemia AML side , could have a positive knock on effect for the MATINS news .
Also , the usual elephant in the room of 'funding' has been dealt with , and access to IPF funding looks also to be underway .
Results presentation moved from Thurs to Friday . Not sure why that would be ? Perhaps they know it may be a busy week .
Mr Tyrrell will lead Greatland's technical team and oversee the transition of Havieron from development to production including the integration of Havieron into the Telfer processing plant.
Full steam ahead at GGP . Shaun sure has put together an 'A'Team .
lots of activity in the last 5 minutes . Looks like many didn't know .
Another FDA approval for a drug championed by LLS .
It got approval despite having only 13% rate complete response ( with about half patients showing some response )
With Bexmab - obviously with smaller numbers - our response rate is far higher .
They had 120 patients - although Bex has now been given to well over 220 patients I think - so plenty of data to back up its mechanism and safety .
https://www.lls.org/news/fda-approves-new-type-btk-inhibitor-treat-mantle-cell-lymphoma?utm_source=Twitter&utm_medium=Social&utm_campaign=01-30-2023-FDA-Approval-Mantle-Cell-Lymphoma-ZGM
A 30% increase in holdings by Varma - equates to about 2.8million euro investment in this placing .
That is a very robust vote of confidence from a very steady institution .
I don't think the 90 day hold will be of much concern to those taking part today .
They , like most , if not all of us , are in here for the big prize .
QIBs are institutional investors that own or manage on a discretionary basis at least $100 million worth of securities.
We have new investors taking part .
If LLS have taken 1 million even that would be great - but leaves pretty much 10 million that's come from elsewhere.
In this financial climate - that's pretty good going - and at a 75% premium from the last placing !
Follow the money
I wonder if they have had investment from any US based outfits -
Last nights RNS stated that they have offered the shares also - in a private placement in the U.S. to a limited number of qualified institutional buyers, or QIBS, pursuant to an exemption from registration under the U.S. Securities Act.
90 days hold on the shares too ( quite short )
So I think , Faron are expecting developments in the next quarter for sure .
3.25 euro - 12 million raised . Oversubscribed .
Gives them working capital to Q3 2023
LLS second investment - no indication of amount , although that may appear on LLS news site
Timo put in 1.3 million euro to maintain his 20% holding
LLS must have put a fair wedge in
I like this -
The Placing was supported by new investors and existing shareholders such as local long-only institutional investors and family offices, Mr. Timo SyrjŠlŠ and The Leukemia & Lymphoma Society Therapy Acceleration Program
Timo has been as solid as a rock - so thanks to him for his support again .
LLS are spending money this month - latest news from them - they invested $3million into Biolnvent last week ( strategic investment)
If they do put in substantial amount ( I think their original entry was about £0.5 million at Faron back in June , although I can't seem to find the figure ) , that would be great .
Surely off the back of Bexmab so far , and all the help they are getting , LLS would now want to take a much larger stake.
https://www.lls.org/therapy-acceleration-program-latest-news
Won't be a disaster if the placing is at 3.5 euro I guess ( if its 11 million )
The last one ( Oct was at 1.85 euro ( 8 million) a 5.5% discount to SP)
So at least they will get more euros for the shares .
If LLS are going in big at Faron , it sure speaks volumes on the experts opinion of where this is going .